NASDAQ:PRTK

Paratek Pharmaceuticals Stock Forecast, Price & News

$4.77
+0.02 (+0.42 %)
(As of 09/21/2021 04:00 PM ET)
Add
Compare
Today's Range
$4.72
$4.90
50-Day Range
$4.70
$6.40
52-Week Range
$4.51
$11.23
Volume269,659 shs
Average Volume494,566 shs
Market Capitalization$232.75 million
P/E RatioN/A
Dividend YieldN/A
Beta1.54
30 days | 90 days | 365 days | Advanced Chart
Receive PRTK News and Ratings via Email

Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Paratek Pharmaceuticals logo

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.06 out of 5 stars

Medical Sector

492nd out of 1,352 stocks

Pharmaceutical Preparations Industry

243rd out of 665 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions

Is Paratek Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Paratek Pharmaceuticals stock.
View analyst ratings for Paratek Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Paratek Pharmaceuticals?

Wall Street analysts have given Paratek Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Paratek Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Paratek Pharmaceuticals' next earnings date?

Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Paratek Pharmaceuticals
.

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) released its earnings results on Monday, August, 9th. The specialty pharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.29 by $0.09. The specialty pharmaceutical company earned $57.49 million during the quarter, compared to analysts' expectations of $59.85 million.
View Paratek Pharmaceuticals' earnings history
.

How has Paratek Pharmaceuticals' stock price been impacted by COVID-19?

Paratek Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PRTK stock has increased by 22.6% and is now trading at $4.77.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PRTK?

4 analysts have issued 12 month price targets for Paratek Pharmaceuticals' stock. Their forecasts range from $10.00 to $28.00. On average, they expect Paratek Pharmaceuticals' share price to reach $16.75 in the next twelve months. This suggests a possible upside of 251.2% from the stock's current price.
View analysts' price targets for Paratek Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the following people:
  • Evan Loh, Chief Executive Officer & Director (LinkedIn Profile)
  • Adam Woodrow, President & Chief Commercial Officer
  • Sarah Higgins, VP, Chief Financial & Accounting Officer
  • Raj Padmanabhan, Vice President-Information Technology
  • Paul McGovern, Vice President-Clinical & Medical Affairs

Who are some of Paratek Pharmaceuticals' key competitors?

What other stocks do shareholders of Paratek Pharmaceuticals own?

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

Who are Paratek Pharmaceuticals' major shareholders?

Paratek Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.17%), Vanguard Group Inc. (4.41%), General American Investors Co. Inc. (2.22%), AIGH Capital Management LLC (1.89%), State Street Corp (1.54%) and Geode Capital Management LLC (1.48%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Evan Loh, Michael Bigham, Randall B Brenner and William M Haskel.
View institutional ownership trends for Paratek Pharmaceuticals
.

Which institutional investors are selling Paratek Pharmaceuticals stock?

PRTK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Morgan Stanley, Morgan Stanley, State of Wisconsin Investment Board, Trellus Management Company LLC, Vanguard Group Inc., and Bank of America Corp DE. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Evan Loh, Michael Bigham, Randall B Brenner, and William M Haskel.
View insider buying and selling activity for Paratek Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Paratek Pharmaceuticals stock?

PRTK stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Marshall Wace LLP, Millennium Management LLC, AIGH Capital Management LLC, Principal Financial Group Inc., State Street Corp, Group One Trading L.P., and General American Investors Co. Inc..
View insider buying and selling activity for Paratek Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $4.77.

How much money does Paratek Pharmaceuticals make?

Paratek Pharmaceuticals has a market capitalization of $232.75 million and generates $46.92 million in revenue each year. The specialty pharmaceutical company earns $-96,540,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis.

How many employees does Paratek Pharmaceuticals have?

Paratek Pharmaceuticals employs 197 workers across the globe.

When was Paratek Pharmaceuticals founded?

Paratek Pharmaceuticals was founded in 1996.

What is Paratek Pharmaceuticals' official website?

The official website for Paratek Pharmaceuticals is www.paratekpharma.com.

Where are Paratek Pharmaceuticals' headquarters?

Paratek Pharmaceuticals is headquartered at 75 PARK PLAZA, BOSTON MA, 02116.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at (617) 807-6600 or via email at [email protected].


This page was last updated on 9/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.